Price (delayed)
$2.81
Market cap
$41.45M
P/E Ratio
0.83
Dividend/share
N/A
EPS
$3.38
Enterprise value
$25.26M
VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
There are no recent dividends present for VYNE.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.